Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Septerna (NASDAQ:SEPN) in a report issued on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $50.00 price target on the stock.

Separately, TD Cowen began coverage on Septerna in a research note on Tuesday. They issued a “buy” rating on the stock.

Septerna Trading Down 3.2 %

NASDAQ:SEPN opened at $21.79 on Tuesday. Septerna has a fifty-two week low of $18.62 and a fifty-two week high of $26.34.

Insider Activity

In other news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of Septerna stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $6,669,000.00. Following the purchase, the insider now directly owns 6,215,591 shares in the company, valued at $111,880,638. The trade was a 6.34 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.